Niki BioSolutions, Inc. (NIKI) Stock Price & Analysis
Niki BioSolutions, Inc. (NIKI) closed at USD 1.83 on Friday, October 23, 2026, down 5.67% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.94; the Oct 23, 2026 session ranged USD 1.81–1.87 on volume of 5,130 shares. Market capitalization is $5.71M, with a 52-week range of USD 1.81–17.2 (NCM). Source: Nexqual, retrieved October 24, 2026 at 12:40 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NIKI.md
Key facts (NIKI)
- Analysts: None.
- Total return with dividends: 1Y -87.7% vs S&P 500 +13.4%; 5Y -99.2% vs S&P 500 +76.9%.
Analysts (NIKI)
Consensus None.
Total return (dividends reinvested) (NIKI)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -87.7% | -99.2% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -87.8% | -62.4% |
| Volatility (annualized) | 96.8% | 129.5% |
| Max drawdown | -88.7% (Nov 2025→Oct 2026) | -99.3% (Nov 2021→Oct 2026) |
NIKI suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Versitech | “Accordingly, Versitech is the only active license agreement we have at this time.” |
Quoted from the company's 20-F filed Mar 27, 2026.
NIKI analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2023) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 12:40 UTC)
| Price | USD 1.83 |
|---|---|
| Change | ▼ 5.67% (down) |
| Previous Close | USD 1.94 |
| Open | USD 1.87 |
| Day Range | USD 1.81 – 1.87 |
| 52-Week Range | USD 1.81 – 17.2 |
| Volume | 5,130 shares |
| Market Cap | $5.71M |
| Exchange | NCM |
Technical Analysis (NIKI)
Nexqual's technical model rates NIKI "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 12:40 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 19.01 (oversold) |
| vs SMA50 | Below (USD 5.27) |
| MACD | -1.03 (negative) |
Analyst Ratings (NIKI)
Wall Street analysts rate NIKI "None", per Nexqual as of October 24, 2026 at 12:40 UTC.
| Consensus Rating | None |
|---|
Earnings (NIKI)
Source: Nexqual, October 24, 2026 at 12:40 UTC.
Financials & Fundamentals (NIKI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -17.05% |
| Debt / Equity | 0.28 |
| Current Ratio | 0.45 |
| Total Cash | $1.83M |
| Total Debt | $3.51M |
Source: Nexqual, October 24, 2026 at 12:40 UTC.
Financial Health Score (NIKI)
Nexqual rates Niki BioSolutions, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 12:40 UTC.
| Growth | Critical — Revenue -16% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $2M cash vs $4M debt |
| Cash Flow | Weak — Operating cash flow -$3M (TTM) |
| Efficiency | Critical — ROE -17%, ROA -10.0% |
Ownership (NIKI)
| Insider Ownership | +47.50% |
|---|---|
| Institutional Ownership | +0.28% |
| Shares Outstanding | 2.94M |
| Short % of Float | +0.51% |
Source: Nexqual, October 24, 2026 at 12:40 UTC.
Leadership (NIKI)
Niki BioSolutions, Inc. is led by Alidad Mireskandari, President, COO & Board Observer, per Nexqual as of October 24, 2026 at 12:40 UTC.
| President, COO & Board Observer | Alidad Mireskandari |
|---|
Major Backers & Investors (NIKI)
Notable institutional backers of Niki BioSolutions, Inc. include Jane Street Group, LLC, according to Nexqual as of October 24, 2026 at 12:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jane Street Group, LLC | 0.2% |
Source: Nexqual, October 24, 2026 at 12:40 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 303.53 | ▼ 1.39% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.27 | ▼ 1.79% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.09 | ▼ 0.35% |
| PRAX | Praxis Precision Medicines, Inc | USD 252.96 | ▼ 2.3% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.93 | ▼ 2.23% |
| AXSM | Axsome Therapeutics, Inc. | USD 145.04 | ▼ 7.07% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 12:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt